Who We Are
About Us
BioInc is ideal for start-ups throughout the Hudson Valley and beyond. For more information about BioInc@ NYMC call us at (914) 594-1999 or use our contact form.
A collaborative environment built to spark innovation and foster entrepreneurial achievement.
BioInc@NYMC is the only biotechnology incubator sited on a health sciences college campus in the Mid-Hudson Valley. Located in the city of Valhalla, New York, BioInc offers turnkey wet labs, dry labs, private offices, and conference rooms specifically designed to support early-stage companies and high-potential entrepreneurs within the biotech and medtech sectors.
We have expanded! Construction is completed and we have added about 10,000 square feet of space to BioInc, comprising 8 new offices, 12 co-working desks, and a beautiful events space. Now accepting applications for startups needing space. Please contact NYMC_BioInc@nymc.edu for more information and to schedule a tour.
Our Culture
We are an organization specifically designed for scientific and entrepreneurial achievement.
BioInc@NYMC’s mission is to focus on delivering unsurpassed support to biotech/medtech start-ups who are transforming the biotechnology industry through research and innovation. Our facility, infrastructure and operational services are aimed at helping early stage businesses and entrepreneurs thrive in order to reach their project goals.
Why BioInc
BioInc provides the ideal environment for discovering and demonstrating biotechnology breakthroughs.
In addition to the cutting-edge core equipment available on-site, BioInc offers an extensive, support-driven infrastructure through NYMC, a fully-equipped health sciences college . As a member of BioInc, startups receive scientific and clinical support, as well as business expertise, to help facilitate a successful project launch. BioInc, a designated START-UP NY site and an Innovation Hot Spot for New York State, offers robust tax credits to all eligible clients.
Our Members
BioInc is proud to be supporting these innovative biomedical startups since its inception.
Current Startups:
Akeso Therapeutics - developing allogenic cell therapy for difficult-to-treat cancers.
Digitouch Health - developing technology to allow anyone to measure their blood pressure with clinical accuracy by pressing a button on a mobile device.
MOE Medical - developing cold electrical plasma systems and therapeutics to treat and remove toenail fungus.
Retia Medical - has developed the ARGOS cardiac output monitor to improve patient care by providing members of the critical care team with a more accurate, easy to use, and affordable hemodynamic monitor that supports confident data-based decisions.
Sapience Therapeutics - developing novel therapeutics for high mortality cancers. Its lead candidate, ST-36 is a peptide-based drug that works as an inhibitor of activating transcription factor 5. ST-36 is designed to promote tumor cell death of glioblastoma multiforme (GBM), the most severe and deadly form of brain cancer.
SHY Therapeutics - developing small molecules therapeutics for the Ras Superfamily of Small GTPases.
Nutrition21 - an industry-leading developer and marketer of efficacious, high-value, clinically substantiated ingredients for use in dietary supplements, functional foods and beverages. With decades of experience, the company’s scientific platform has continued to create unique, patented products that are both safe and clinically effective. To build consumer trust, Nutrition21 ensures product efficacy and safety through a product development process that involves rigorous preclinical and clinical research. The company currently holds over 100 domestic and international issued and pending patents for its ingredients which support unique claims associated with sports nutrition, weight management, cognitive health, and beauty-from-within, among others.
Ny.TmT - developing innovative technologies and therapeutic products for musculoskeletal diseases such as tendinopathy and osteoarthritis.
Graduated Startups:
Affina Biotechnologies - developing a first-in-class treatment for late stage ovarian cancer.
MediSprout - has developed a telemedicine platform to connect patients to their own doctors using a clinical HIPAA-compliant video communication solution.
Sweet Defeat/Crave Crush - has developed a mint-flavored lozenge that is clinically proven to reduce consumption of and desire for high-sugar foods.